60 Recruiting Multiple Myeloma Phase 1 Clinical Trials
Active phase 1 studies for multiple myeloma enrolling across the USA. Verify eligibility and contact site coordinators.
All Multiple Myeloma studiesPhase 1 Studies for Multiple Myeloma
Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 Hackensack University Medical Center — Hackensack, New Jersey
View Study & Checklist ➔A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
📍 City of Hope — Goodyear, Arizona
View Study & Checklist ➔Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
View Study & Checklist ➔Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
📍 Emory University — Atlanta, Georgia
View Study & Checklist ➔Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
📍 University of California Davis — Davis, California
View Study & Checklist ➔Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Arizona /ID# 260799 — Phoenix, Arizona
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Salvador, Estado de Bahia
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
📍 Lineberger Comprehensive Cancer Center at University of North Carolina — Chapel Hill, North Carolina
View Study & Checklist ➔Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
📍 Harris Health Ben Taub Hospital — Houston, Texas
View Study & Checklist ➔Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
📍 Mayo Clinic Hospital — Phoenix, Arizona
View Study & Checklist ➔Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
📍 GSK Investigational Site — Westwood, Kansas
View Study & Checklist ➔A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
📍 Icahn School of Medicine — New York, New York
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
📍 University of Colorado — Aurora, Colorado
View Study & Checklist ➔TriPRIL CAR T Cells in Multiple Myeloma
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
📍 GSK Investigational Site — Boston, Massachusetts
View Study & Checklist ➔A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
📍 Weill Cornell Medical College — New York, New York
View Study & Checklist ➔BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
View Study & Checklist ➔Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
📍 Yale New Haven Hospital — New Haven, Connecticut
View Study & Checklist ➔Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
📍 Univ. of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
📍 238995 — Atlanta, Georgia
View Study & Checklist ➔A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680 — San Francisco, California
View Study & Checklist ➔A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
📍 Local Institution - 102 — Scottsdale, Arizona
View Study & Checklist ➔Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
📍 Levine Cancer Institute — Charlotte, North Carolina
View Study & Checklist ➔Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
📍 Icahn School of Medicine at Mount Sinai — New York, New York
View Study & Checklist ➔²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
📍 City of Hope National Medical Center /ID# 273132 — Duarte, California
View Study & Checklist ➔ATRA and Carfilzomib in Plasma Cell Myeloma Patients
📍 Houston Methodist Neal Cancer Center — Houston, Texas
View Study & Checklist ➔Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
📍 Winship Cancer Institute of Emory University — Atlanta, Georgia
View Study & Checklist ➔64Cu-LLP2A for Imaging Hematologic Malignancies
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
📍 Research Site — Phoenix, Arizona
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
📍 University of Southern California /ID# 272414 — Los Angeles, California
View Study & Checklist ➔Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
📍 Global Oncology, Inc. — Alhambra, California
View Study & Checklist ➔Selinexor and Backbone Treatments of Multiple Myeloma Patients
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔Personalized Autologous Transplant for Multiple Myeloma
📍 Winship Cancer Institute of Emory University — Atlanta, Georgia
View Study & Checklist ➔A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
📍 Research Site — Duarte, California
View Study & Checklist ➔